Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
about
Malignant mesotheliomaCurrent issues in malignant pleural mesothelioma evaluation and managementGuidelines for the diagnosis and treatment of malignant pleural mesotheliomaNovel systemic therapy against malignant pleural mesothelioma.Investigational approaches for mesothelioma.Pemetrexed in thoracic cancer.Chemotherapy and targeted therapies for unresectable malignant mesotheliomaBTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112Malignant pleural mesothelioma--an update.Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial.Mesothelioma: a review.Pemetrexed-cisplatin combination in mesothelioma.Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma.Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.Emerging drugs for mesothelioma.Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesotheliomaCurrent concepts in malignant pleural mesothelioma.Current therapies for malignant pleural mesotheliomaGemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810)Systemic treatments for mesothelioma: standard and novel.Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG).Future developments in the management of malignant pleural mesothelioma.Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies.Translational therapies for malignant pleural mesothelioma.Raltitrexed in mesothelioma.Systemic treatment of malignant pleural mesothelioma.Asbestos-related pleuropulmonary diseases: benign and malignant.The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms.Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis.Medical and oncological management of malignant mesothelioma.Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma.A catalogue of treatment and technologies for malignant pleural mesothelioma.Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects.Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data.Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients.Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum.Glutathione S-transferase P1-1 as a target for mesothelioma treatment.
P2860
Q21202901-F9058683-09DC-448A-A64B-002078CAD2B8Q28393560-BC402164-1204-4A76-A2CB-A2C2E40EDE1CQ28394028-9C0C6FF8-638A-436A-9F71-216C86E1E898Q33890499-26A100CE-660D-4328-9F5B-51058CA6B928Q34293068-06A82128-6CA0-486C-874F-91C26FF6DC29Q34516941-C0C50D55-191C-467D-AC9E-F4D698996D15Q35141369-1F973EEE-9CA7-4373-B40D-820721F57AFEQ35536471-67CAA073-6943-4CEE-98C2-593EB89170AAQ35740408-1A3B7D86-3A67-470F-8CB8-9810B141F4B4Q35782906-A6723C1B-04DF-4782-A089-9E3130D91712Q35832320-1232CA58-7BB4-46DD-8951-24480DA1153BQ35839385-A69ACD09-48A7-43A7-B98F-146ADE6E884BQ36118385-FDC158DC-261D-4733-85F0-BB260FC22A13Q36425940-1ACB7A93-3E90-4AC2-ACE1-992E522C6A1BQ36755228-7310D74A-388B-4336-A54D-510773E15CB2Q36758593-7B1BFFCB-205F-4319-8E76-4180189D0840Q36822893-F72B2EEE-D4BA-4315-B6EF-E6F1A2602A73Q37086026-19A61A50-0967-4409-9989-7466E8F2D39AQ37232309-9B217E46-8466-498D-8B43-565FD7CA5A69Q37243005-89C258B8-CD9D-4ABA-B930-A78FF4EE2A23Q37260408-5CFB79A1-6D94-44ED-814A-D17782E17646Q37277434-12060251-944F-4843-B98B-4BA7FEB07CB4Q37449036-4D4F3D21-437F-4483-8E00-F3B5A91572EAQ37729428-2F141F5C-FFA0-4411-BB6D-E5244CC89FC9Q37734455-AE18F802-4A25-4F16-A841-FED76556C808Q37945636-BF76188C-1F0C-4BCB-BDAC-BA3F810F3293Q37992694-A1990D3A-54FF-499E-8172-6BB32C16A3DBQ38018217-B2EECFD8-CE0C-4DE4-8804-347653457175Q38148036-5ABF2470-3B20-4F9A-BA06-9A3FE96F26D6Q38244051-476A9E02-36CD-4369-80C0-4B421DDBDBE6Q38542421-BD66631A-5F73-4384-AD1C-1D5E1E858583Q38633115-A842413A-1A5B-4E75-BDC4-5A90AF74EC6CQ38760623-52213367-2E37-4E10-9978-24DE19EB594FQ39350596-E548099A-132B-473E-8490-3EC0900D5479Q39718655-C3E97889-1CC2-4847-B5C0-DC0895C48C3CQ40041012-F287BCC0-52DF-4495-9EDE-03F59639E680Q43466291-C96B3EFD-77C8-4CAE-B252-26CAF7386EEAQ44537561-18DEA6FF-9118-4794-9582-45F5D85C8625Q54473737-5F8567DA-1B1C-4C98-94FD-125431773036
P2860
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Activity of chemotherapy and i ...... literature with meta-analysis.
@ast
Activity of chemotherapy and i ...... literature with meta-analysis.
@en
Activity of chemotherapy and i ...... literature with meta-analysis.
@nl
type
label
Activity of chemotherapy and i ...... literature with meta-analysis.
@ast
Activity of chemotherapy and i ...... literature with meta-analysis.
@en
Activity of chemotherapy and i ...... literature with meta-analysis.
@nl
prefLabel
Activity of chemotherapy and i ...... literature with meta-analysis.
@ast
Activity of chemotherapy and i ...... literature with meta-analysis.
@en
Activity of chemotherapy and i ...... literature with meta-analysis.
@nl
P2093
P921
P1433
P1476
Activity of chemotherapy and i ...... literature with meta-analysis.
@en
P2093
Berghmans T
Louviaux I
Paesmans M
Sculier JP
P304
P356
10.1016/S0169-5002(02)00180-0
P577
2002-11-01T00:00:00Z